551 related articles for article (PubMed ID: 25671669)
21. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
[TBL] [Abstract][Full Text] [Related]
22. How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.
Appadurai R; Senapati S
Biochemistry; 2017 Jun; 56(23):2907-2920. PubMed ID: 28505418
[TBL] [Abstract][Full Text] [Related]
23. Accurate ensemble molecular dynamics binding free energy ranking of multidrug-resistant HIV-1 proteases.
Sadiq SK; Wright DW; Kenway OA; Coveney PV
J Chem Inf Model; 2010 May; 50(5):890-905. PubMed ID: 20384328
[TBL] [Abstract][Full Text] [Related]
24. Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
Agniswamy J; Shen CH; Wang YF; Ghosh AK; Rao KV; Xu CX; Sayer JM; Louis JM; Weber IT
J Med Chem; 2013 May; 56(10):4017-27. PubMed ID: 23590295
[TBL] [Abstract][Full Text] [Related]
25. Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.
Leonis G; Czyżnikowska Ż; Megariotis G; Reis H; Papadopoulos MG
J Chem Inf Model; 2012 Jun; 52(6):1542-58. PubMed ID: 22587384
[TBL] [Abstract][Full Text] [Related]
26. The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.
Ahmed SM; Maguire GE; Kruger HG; Govender T
Chem Biol Drug Des; 2014 Apr; 83(4):472-81. PubMed ID: 24267738
[TBL] [Abstract][Full Text] [Related]
27. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
28. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
Seibold SA; Cukier RI
Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
[TBL] [Abstract][Full Text] [Related]
29. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
Hong L; Zhang XC; Hartsuck JA; Tang J
Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
[TBL] [Abstract][Full Text] [Related]
31. Interdependence of Inhibitor Recognition in HIV-1 Protease.
Paulsen JL; Leidner F; Ragland DA; Kurt Yilmaz N; Schiffer CA
J Chem Theory Comput; 2017 May; 13(5):2300-2309. PubMed ID: 28358514
[TBL] [Abstract][Full Text] [Related]
32. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
Kar P; Lipowsky R; Knecht V
J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
[TBL] [Abstract][Full Text] [Related]
33. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor.
Nivesanond K; Peeters A; Lamoen D; Van Alsenoy C
J Chem Inf Model; 2008 Jan; 48(1):99-108. PubMed ID: 18173253
[TBL] [Abstract][Full Text] [Related]
34. Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding.
Cai Y; Schiffer C
Methods Mol Biol; 2012; 819():551-60. PubMed ID: 22183557
[TBL] [Abstract][Full Text] [Related]
35. Effect of T68A/N126Y mutations on the conformational and ligand binding landscape of Coxsackievirus B3 3C protease.
Bhakat S
Mol Biosyst; 2015 Aug; 11(8):2303-11. PubMed ID: 26077945
[TBL] [Abstract][Full Text] [Related]
36. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
C S V; Tamizhselvi R; Munusami P
J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
[TBL] [Abstract][Full Text] [Related]
37. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations.
Badaya A; Sasidhar YU
Sci Rep; 2020 Mar; 10(1):5501. PubMed ID: 32218488
[TBL] [Abstract][Full Text] [Related]
39. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
40. Molecular dynamics and ligand docking of a hinge region variant of South African HIV-1 subtype C protease.
Zondagh J; Balakrishnan V; Achilonu I; Dirr HW; Sayed Y
J Mol Graph Model; 2018 Jun; 82():1-11. PubMed ID: 29625416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
